European regulators will review the multiple sclerosis drug Tysabri made by Elan (NYSE: ELN) and Biogen (Nasdaq: BIIB) after 23 reported cases of the brain infection progressive multifocal leukoencephalopathy. Shares of Elan tumbled $1.14 to $5.30 while Biogen stock dropped $2.47 to $44.76.
European Regulators To Review Elan's and Biogen's Tysabri
October 23, 2009 at 14:23 PM EDT